Published in BMC Physiol on July 21, 2003
Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med (2011) 1.88
Anti-inflammatory and pro-angiogenic effects of beta blockers in a canine model of chronic ischemic cardiomyopathy: comparison between carvedilol and metoprolol. Basic Res Cardiol (2013) 0.83
Human cardiac tissue in a microperfusion chamber simulating extracorporeal circulation--ischemia and apoptosis studies. J Cardiothorac Surg (2010) 0.77
Role of β-blocker therapy in pediatric heart failure. Ped Health (2010) 0.75
Effects of β-adrenoceptor subtypes on cardiac function in myocardial infarction rats exposed to fine particulate matter (PM 2.5). Biomed Res Int (2014) 0.75
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med (1996) 12.77
Apoptosis in the failing human heart. N Engl J Med (1997) 6.35
Apoptosis in myocytes in end-stage heart failure. N Engl J Med (1996) 6.19
Oxidative stress as a mediator of apoptosis. Immunol Today (1994) 5.80
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation (1996) 4.01
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol (1995) 3.12
Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation (1992) 2.88
Transcriptional regulation during cardiac growth and development. Annu Rev Physiol (1993) 2.33
Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest (1996) 2.21
Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation (1996) 2.01
Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res (1998) 2.01
Death by design. Programmed cell death in cardiovascular biology and disease. Circ Res (1997) 1.76
Carvedilol. N Engl J Med (1998) 1.74
Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest (1998) 1.73
Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest (1996) 1.65
Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am J Physiol (1997) 1.56
Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol (1995) 1.55
Adrenergic regulation of cardiac myocyte apoptosis. J Cell Physiol (2001) 1.52
Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol (1996) 1.52
Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. J Am Coll Cardiol (1999) 1.51
Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol (1997) 1.39
Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol (1996) 1.37
Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation (1994) 1.36
Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol (2000) 1.22
Methods for detecting and quantifying apoptosis. Curr Top Dev Biol (1998) 1.16
Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. J Am Coll Cardiol (2000) 1.02
Myocyte nuclear mitotic division and programmed myocyte cell death characterize the cardiac myopathy induced by rapid ventricular pacing in dogs. Lab Invest (1995) 1.02
Effect of beta-blockers on free radical-induced cardiac contractile dysfunction. Circulation (1999) 0.97
Apoptosis in hypertensive heart disease. Curr Opin Cardiol (1998) 0.95
Furazolidone-induced cardiac dilatation in turkeys. Avian Dis (1973) 0.91
Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. Am J Physiol (1999) 0.87
Life and death in the cardiovascular system. Circulation (1997) 0.87
Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol (1994) 0.85
Effects of furazolidone on the development of cardiomyopathies in turkey poults. Avian Dis (1974) 0.84
Pathophysiological and biochemical characterisation of an avian model of dilated cardiomyopathy: comparison to findings in human dilated cardiomyopathy. Cardiovasc Res (1993) 0.83
Cell death in the failing heart: role of an unnatural growth response to overload. Clin Cardiol (1995) 0.81
Beta-blocker treatment of dilated cardiomyopathy. Beneficial effect of carteolol in mice. Circulation (1991) 0.76
Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat Med (2007) 3.98
Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med (2012) 3.53
Functional near-infrared fluorescence imaging for cardiac surgery and targeted gene therapy. Mol Imaging (2002) 3.37
Titin isoform switch in ischemic human heart disease. Circulation (2002) 3.05
Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail (2009) 2.89
Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res (2005) 2.52
PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest (2005) 2.36
Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol (2008) 2.29
Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res (2013) 2.12
In vivo tracking of stem cells for clinical trials in cardiovascular disease. Circulation (2004) 2.11
Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res (2012) 2.06
Effects of Na(+)/Ca(2+)-exchanger overexpression on excitation-contraction coupling in adult rabbit ventricular myocytes. J Mol Cell Cardiol (2002) 2.00
Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci U S A (2002) 1.98
Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol (2002) 1.97
Critical role for stromal interaction molecule 1 in cardiac hypertrophy. Circulation (2011) 1.91
SUMO1-dependent modulation of SERCA2a in heart failure. Nature (2011) 1.89
PICOT inhibits cardiac hypertrophy and enhances ventricular function and cardiomyocyte contractility. Circ Res (2006) 1.80
Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med (2013) 1.78
Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci U S A (2004) 1.77
Angiotensin II-induced negative inotropy in rat ventricular myocytes: role of reactive oxygen species and p38 MAPK. Am J Physiol Heart Circ Physiol (2005) 1.73
Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer. Mol Ther (2006) 1.71
Targeted sarcoplasmic reticulum Ca2+ ATPase 2a gene delivery to restore electrical stability in the failing heart. Circulation (2012) 1.71
Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation (2009) 1.71
Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J Am Coll Cardiol (2008) 1.70
Stem cell factor gene transfer promotes cardiac repair after myocardial infarction via in situ recruitment and expansion of c-kit+ cells. Circ Res (2012) 1.68
Cardiac sodium channel gene variants and sudden cardiac death in women. Circulation (2007) 1.67
PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling. Circ Res (2008) 1.66
CaMKII inhibition protects against necrosis and apoptosis in irreversible ischemia-reperfusion injury. Cardiovasc Res (2006) 1.64
Increased leakage of sarcoplasmic reticulum Ca2+ contributes to abnormal myocyte Ca2+ handling and shortening in sepsis. Crit Care Med (2005) 1.63
SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure. Sci Transl Med (2013) 1.59
Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes. J Mol Cell Cardiol (2011) 1.55
Inhibition of PKCα/β with ruboxistaurin antagonizes heart failure in pigs after myocardial infarction injury. Circ Res (2011) 1.55
Targeting phospholamban by gene transfer in human heart failure. Circulation (2002) 1.55
Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol (2007) 1.54
Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury. Circ Res (2009) 1.52
Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol (2004) 1.46
Gene therapy for heart failure. Circ Res (2012) 1.46
Targeted SERCA2a gene expression identifies molecular mechanism and therapeutic target for arrhythmogenic cardiac alternans. Circ Arrhythm Electrophysiol (2009) 1.44
Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J Mol Cell Cardiol (2009) 1.42
Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle. J Clin Invest (2011) 1.42
AKT signalling in the failing heart. Eur J Heart Fail (2011) 1.41
Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure. Expert Opin Biol Ther (2010) 1.41
Severe hyperosmolar metabolic acidosis due to a large dose of intravenous lorazepam. N Engl J Med (2002) 1.40
SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure. Circ Arrhythm Electrophysiol (2011) 1.40
Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol (2008) 1.35
A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol (2011) 1.35
Distinct roles of microRNA-1 and -499 in ventricular specification and functional maturation of human embryonic stem cell-derived cardiomyocytes. PLoS One (2011) 1.34
Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther (2011) 1.34
Sarco/endoplasmic reticulum Ca2+-ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat. Circ Res (2005) 1.33
CXCR4 modulates contractility in adult cardiac myocytes. J Mol Cell Cardiol (2006) 1.31
Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase pump overexpression in a porcine model of ischemia reperfusion. Circulation (2008) 1.30
Localization and quantification of platelet-rich thrombi in large blood vessels with near-infrared fluorescence imaging. Circulation (2006) 1.28
Novel technique of aortic banding followed by gene transfer during hypertrophy and heart failure. Physiol Genomics (2002) 1.27
The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis. J Mol Cell Cardiol (2010) 1.27
Plasticity of surface structures and β(2)-adrenergic receptor localization in failing ventricular cardiomyocytes during recovery from heart failure. Circ Heart Fail (2012) 1.23
The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases. Nat Clin Pract Cardiovasc Med (2008) 1.21
Early repair of moderate ischemic mitral regurgitation reverses left ventricular remodeling: a functional and molecular study. Circulation (2007) 1.20
SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells. Mol Ther (2010) 1.18
A novel mutant cardiac troponin C disrupts molecular motions critical for calcium binding affinity and cardiomyocyte contractility. Biophys J (2008) 1.18
Toll-like receptor 2 activation by bacterial peptidoglycan-associated lipoprotein activates cardiomyocyte inflammation and contractile dysfunction. Crit Care Med (2007) 1.16
Ca2+ cycling and new therapeutic approaches for heart failure. Circulation (2010) 1.16
Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium. FASEB J (2013) 1.15
Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy. Nat Rev Cardiol (2012) 1.15
Shrink-film configurable multiscale wrinkles for functional alignment of human embryonic stem cells and their cardiac derivatives. Adv Mater (2011) 1.14
Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome. J Clin Invest (2014) 1.13
Small molecule-mediated directed differentiation of human embryonic stem cells toward ventricular cardiomyocytes. Stem Cells Transl Med (2013) 1.13
Targeting calcium cycling proteins in heart failure through gene transfer. J Physiol (2003) 1.12
Quantitation of CXCR4 expression in myocardial infarction using 99mTc-labeled SDF-1alpha. J Nucl Med (2008) 1.12
Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat Clin Pract Cardiovasc Med (2008) 1.12
Rescuing the failing heart by targeted gene transfer. J Am Coll Cardiol (2011) 1.11
In vivo cardiac gene transfer of Kv4.3 abrogates the hypertrophic response in rats after aortic stenosis. Circulation (2004) 1.11
Effects of CXCR4 gene transfer on cardiac function after ischemia-reperfusion injury. Am J Pathol (2010) 1.10
Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model. Am J Physiol Heart Circ Physiol (2006) 1.09
Amniotic fluid cells are more efficiently reprogrammed to pluripotency than adult cells. Cell Reprogram (2010) 1.08
Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy. Circulation (2010) 1.08
Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc (2013) 1.08
β2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J Cardiovasc Pharmacol (2010) 1.08
Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol (2006) 1.06
SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. Eur Heart J (2012) 1.05